当前,肥胖已成为全球严峻的慢性疾病挑战之一。有数据显示,目前全球超过6.5亿成年人受到肥胖困扰。而作为多种慢性病的核心危险因素,肥胖显著增加2型糖尿病、心血管疾病乃至部分癌症的发病风险,对公众健康构成深远挑战,药物市场巨大。据悉,在减重药物领域,GLP-1类药物成为热门赛道,国内一批药企也积极抢占这一赛道,并逐渐迎来收获。如2026年3月7日,翰森制药宣布,其自主研发的GLP-1/GIP双受体...
Source Link当前,肥胖已成为全球严峻的慢性疾病挑战之一。有数据显示,目前全球超过6.5亿成年人受到肥胖困扰。而作为多种慢性病的核心危险因素,肥胖显著增加2型糖尿病、心血管疾病乃至部分癌症的发病风险,对公众健康构成深远挑战,药物市场巨大。据悉,在减重药物领域,GLP-1类药物成为热门赛道,国内一批药企也积极抢占这一赛道,并逐渐迎来收获。如2026年3月7日,翰森制药宣布,其自主研发的GLP-1/GIP双受体...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.